Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 7/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.68 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.62 |
| ▸ | HTR3B | O95264 | 5/20 | 0.62 |
| ▸ | HTR3A | P46098 | 5/20 | 0.62 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.62 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
| ▸ | HTR1A | P08908 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443521 | 0.88 | ADRB1 (1.00) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL18577062 | 0.86 | ADRB1 (0.96) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL7229934 | 0.84 | ADRB1 (0.55) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL254693 | 0.82 | ADRB1 (1.00) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2873315 | 0.81 | ADRB1 (0.80) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5686228 | 0.81 | ADRB1 (0.86) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8891314 | 0.80 | ADRB1 (0.77) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5682967 | 0.80 | ADRB1 (0.77) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL17893823 | 0.80 | ADRB1 (0.49) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL6965885 | 0.80 | ADRB1 (0.96) | ADRB1CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468955-B1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3468955-B1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV (BE) | 2020-11-10 | — | — | US | disclosed |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV (BE) | 2020-11-10 | — | — | US | disclosed |
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-17 | — | — | US | disclosed |
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-17 | — | — | US | disclosed |
| WO-2017211666-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2017-12-14 | — | — | WO | disclosed |
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1750727-A2 | KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005117909-A2 | KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | ADAMTS5, ADAMTS4, ADAMTS1 | ADRB1 3589/4885CHRM2 4257/4885CHRM4 4010/4885 |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | ADAMTS5, ADAMTS4, ADAMTS1 | ADRB1 3589/4885CHRM2 4257/4885CHRM4 4010/4885 |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | ADRB1 1852/4885CHRM2 1610/4885CHRM4 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.